Experimental infections of baboons (Papio spp.) and vervet monkeys (Cercopithecus aethiops) with Trichinella zimbabwensis and successful treatment with ivermectin.
Experimental Trichinella zimbabwensis infections were established in three baboons (Papio sp.) and four vervet monkeys (Cercopithecus aethiops) and the clinical-pathological manifestations assessed. The infected animals showed clinical signs ranging from fever, diarrhoea, periorbital oedema and muscular pain in varying degrees. One baboon became blind due to the infection. Levels of creatinine phosphokinase and lactate dehydrogenase increased to reach a peak on Day 42 post-infection (pi) for both baboons and monkeys. Blood parameters such as packed cell volume, levels of red blood cells and white blood cells did not change significantly from the normal ranges except for the levels of eosinophils which peaked above the normal ranges at Day 28 and 56 pi in baboons and at Day 56 pi in monkeys. Two baboons and two monkeys died during the course of the experiment. They were emaciated and showed lesions such as ascites, hydropericardium, congested liver and enlarged gall bladder. Histopathological findings of various muscles included a basophilic transformation of muscle cells, the disappearance of sarcomere myofibrils and basophilic sarcoplasm with the presence of Trichinella larvae in the sarcoplasm. These changes were mainly in the massetter and were of various intensities in the tail, gastrocnemius and biceps muscles. Five consecutive treatments with an oxfendazole-levamisole combination on surviving animals failed to clear the infection whereas ivermectin cleared the infection after one treatment in two monkeys and after two treatments in a baboon.
Mukaratirwa
S
S
Department of Paraclinical Veterinary Studies, Faculty of Veterinary Science, University of Zimbabwe, P.O. Box MP 167 Mount Pleasant Harare, Zimbabwe. mukaratirwa@ukzn.ac.za
Dzoma
B M
BM
Matenga
E
E
Ruziwa
S D
SD
Sacchi
L
L
Pozio
E
E
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D008992:Monkey Diseases / Q000188:drug therapy* / Q000473:pathology; D010215:Papio; D013997:Time Factors; D016896:Treatment Outcome; D014234:Trichinella / Q000187:drug effects / Q000254:growth & development; D014235:Trichinellosis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*
D000871:Anthelmintics; D007559:Ivermectin